Los Angeles Capital Management LLC Sells 11,044 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Los Angeles Capital Management LLC decreased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 11.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 86,533 shares of the biotechnology company’s stock after selling 11,044 shares during the period. Los Angeles Capital Management LLC’s holdings in BioCryst Pharmaceuticals were worth $658,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of BCRX. CWM LLC increased its position in BioCryst Pharmaceuticals by 200.0% during the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 3,772 shares in the last quarter. Signaturefd LLC grew its stake in shares of BioCryst Pharmaceuticals by 560.5% during the second quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock worth $41,000 after buying an additional 5,599 shares during the last quarter. Seven Eight Capital LP acquired a new position in shares of BioCryst Pharmaceuticals during the first quarter worth $57,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of BioCryst Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 1,322 shares during the last quarter. Finally, Natixis boosted its holdings in shares of BioCryst Pharmaceuticals by 400.6% during the 1st quarter. Natixis now owns 11,684 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 9,350 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on BCRX shares. StockNews.com raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th. Barclays lifted their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. Needham & Company LLC reiterated a “buy” rating and set a $14.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $14.67.

BioCryst Pharmaceuticals Stock Down 5.6 %

BCRX opened at $7.03 on Friday. The stock has a market cap of $1.46 billion, a PE ratio of -11.52 and a beta of 1.89. BioCryst Pharmaceuticals, Inc. has a twelve month low of $4.03 and a twelve month high of $8.88. The company has a fifty day moving average of $7.70 and a 200-day moving average of $7.14.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, hitting the consensus estimate of ($0.07). The business had revenue of $117.10 million during the quarter, compared to the consensus estimate of $113.99 million. During the same period last year, the business posted ($0.19) earnings per share. The business’s revenue was up 35.1% on a year-over-year basis. Sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.